Featured Products
Welcome
At Amneal we are committed to forming deep relationships with our customers and business partners as well as creating strong value throughout the supply chain. That’s why we've created this website. Get to know Amneal, as a company, partner, supplier, employer or customer. At amneal.com we provide valuable information about our operations, leaders, products, business principles and more… as well as details on how to get in touch with us.
Welcome to Amneal Pharmaceuticals—generic’s new generation. We encourage you to learn more about our remarkable company. Explore our site.
News and Press
AMNEAL GETS APPROVAL FOR GENERIC SUBOXONE®
Amneal has received FDA approval for one of the first generic versions of Suboxone® sublingual tablets for maintenance treatment of opioid drug dependence. Generic buprenorphine hydrochloride (HCl) and naloxone HCl dihydrate sublingual tablets are now available in 2 mg/0.5 mg and 8 mg/2 mg strengths, both in 30-count bottles.
More »
Amneal has received FDA approval for one of the first generic versions of Suboxone® sublingual tablets for maintenance treatment of opioid drug dependence. Generic buprenorphine hydrochloride (HCl) and naloxone HCl dihydrate sublingual tablets are now available in 2 mg/0.5 mg and 8 mg/2 mg strengths, both in 30-count bottles.
More »
AMNEAL PARTNERS WITH HANMI TO MARKET NEXIUM® ALTERNATIVE
Amneal Pharmaceuticals, LLC today announced that it has entered into a license and distribution agreement with South Korea-based Hanmi Pharmaceutical Co., Ltd to acquire exclusive distribution rights to Hanmi's new drug application (NDA), currently under FDA review, for esomeprazole strontium delayed-release capsules....
More »
Amneal Pharmaceuticals, LLC today announced that it has entered into a license and distribution agreement with South Korea-based Hanmi Pharmaceutical Co., Ltd to acquire exclusive distribution rights to Hanmi's new drug application (NDA), currently under FDA review, for esomeprazole strontium delayed-release capsules....
More »
AMNEAL PHARMACEUTICALS BUCKS TREND AND ADDS U.S. MANUFACTURING JOBS WITH MAJOR EXPANSION
Amneal Pharmaceuticals, LLC today announced that the company is investing $120 million in physical plant capital expenditures from 2012-2014 to significantly grow its operations at three of its six current U.S. R&D, manufacturing and distribution facilities...
More »
Amneal Pharmaceuticals, LLC today announced that the company is investing $120 million in physical plant capital expenditures from 2012-2014 to significantly grow its operations at three of its six current U.S. R&D, manufacturing and distribution facilities...
More »